| |MAY 20269VENUS REMEDIES GETS ARGENTINA NOD FOR KEY ANTIBIOTICWEIGHT LOSS DRUGS MAY CHANGE BRAIN'S PLEASURE RESPONSEYEIDA-JAPAN MEDICAL DEVICES DEAL TO BOOST MEDTECH HUBIS INDIA'S PRIVATE HEALTHCARE CRISIS PUTTING AYUSHMAN AT RISK?India-based Venus Remedies has secured marketing approval in Argentina for its antibiotic drug used to treat serious bacterial infections, marking another step in the company's global expansion strategy. The approval allows the pharmaceutical company to commercialize its antibiotic product in the South American nation, strengthening its footprint in the Latin American healthcare market.The approved drug, Meropenem + Sulbactam, is designed to treat a wide range of bacterial infections, including complicated infections caused by resistant bacteria. The company said the New research on weight loss drugs suggests these medications may affect more than appetite and body weight. Scientists have found that newer GLP-1-based treatments could alter the brain's reward system, potentially changing how people experience pleasure, cravings, and motivation. The study, published in Nature by researchers at the University of Virginia, examined newer oral GLP-1 drugs including Danuglipron and Orforglipron. While these medications are designed to help people lose weight by controlling hunger, researchers discovered they may also influence brain pathways linked to reward and pleasure. According to the researchers, the drugs affected communication between the hindbrain, amygdala, and dopamine-producing neurons. These areas help regulate how the brain responds to rewarding experiences, including eating highly desirable foods. The findings may explain why many patients taking GLP-1 medications report a drop in "food noise" and reduced cravings. POThe medical devices sector in India received a major push after the (YEIDA) signed a memorandum of understanding with (MEJ) to strengthen manufacturing, technology transfer, and investment in the industry. The agreement aims to position Uttar Pradesh as a leading medtech hub with support from India's private healthcare crisis is raising serious concerns about the future of affordable treatment for millions of patients. Several leading private hospital chains are reconsidering their participation in government-backed health schemes like Ayushman Bharat, CGHS, and ECHS, citing delayed payments, low reimbursement rates, and rising treatment costs.The private healthcare crisis has also triggered fears that patients depending on cashless treatment may soon face fewer hospital options, longer waiting periods, and higher out-of-pocket expenses. The issue is no longer limited to boardrooms and policy meetings. It is beginning to affect how hospitals manage admissions under public healthcare schemes across India.POwith seven observations under Form 483, a document issued by the USFDA when investigators identify conditions that may need corrective action. The company, however, clarified that none of the observations were related to data integrity, which is considered one of the most serious compliance concerns in the pharmaceutical industry. POapproval was granted by Argentina's drug regulatory authority after a detailed review process. Speaking on the development, Venus Remedies President and Director Saransh Chaudhary said, "This approval is a testament to our commitment to delivering high-quality and innovative antimicrobial therapies across global markets." POJapanese companies and healthcare experts.The partnership will focus on the upcoming Medical Device Park being developed by YEIDA near Greater Noida along the Yamuna Expressway. The project is expected to attract Japanese medical technology firms looking to expand their presence in India. Officials said the collaboration will encourage research partnerships, startup growth, skill development, and advanced manufacturing in the healthcare industry. PO
< Page 8 | Page 10 >